Applying Janus Kinase 2 (JAK2) Inhibitors to the Treatment of Chronic Myelofibrosis

Course Information

Therapautic Area: Hematology
Credit(s): N/A
Activity Dates: June 24, 2014 - June 23, 2015


This course is still available as a learning tool but has expired for CME credit.

Program Overview

With the advent of JAK2 inhibitors, viable, clinically important treatment options are now becoming available and there is a clear need for focused educational efforts on the diagnosis and prognostic risk-based treatment approaches to myelofibrosis.

This unique webcast will be led and developed by a panel of expert physicians who specialize in myelofibrosis. The challenges of clinical practice with regard to appropriate diagnosis, pathophysiology, patient education, improving adherence, and clinical trial data will be presented and discussed. Clinical decision making utilizing a case-based approach will also be incorporated.

Target Audience

Hematologists-Oncologists, Oncologists, and other clinicians involved in the management and treatment of patients with myelofibrosis.

Learning Objectives

  1. Discuss advances in MF science, particularly the role of JAK mutations in myelofibrosis
  2. Analyze recent clinical trial data of JAK 1/2 inhibitors in myelofibrosis
  3. Implement individualized treatment plans that incorporate current JAK 2 inhibitor clinical trial data, patient education, and strategies to improve adherence



Co-provided by the Elsevier Office of Continuing Medical Education and AcademicCME

eocme acme logo